Sotorasib and adagrasib were first accepted by the US FDA for treating KRAS G12C–mutated advanced lung cancer and were subsequently studied in refractory advanced studies in colon cancer (Hong et al., 2020; Kim et al., 2020; Fakih et al., 2022) showed that sotorasib and adagrasib had single-agent efficiencies of 10%–22%, achieving a breakthrough in targeted therapy for RAS-mutant colon cancer. Here, KRAS is linked to malignant colon neoplasm.